Third time the charm for Alzheimer's drug?

Share this article:

Eli Lilly's experimental Alzheimer's treatment was ruled a failure in two earlier trials. But when investigators combined solanezumab's data from both tests, they discovered that cognitive declines were slowed by 34% among patients who started out with mild symptoms. Based on those results, solanezumab has been selected for a federally sponsored study for people who have not yet suffered significant memory loss. Brigham and Women's Hospital is helping coordinate the three-year investigation, which could cost up to $100 million."This is the first time investigators will test an amyloid-clearing drug in older individuals thought to be in the pre-symptomatic stage of Alzheimer's disease," the hospital announced. They are hoping the medication will reduce memory decline by 30%.

Share this article:

More in Products

Aviv REIT offers public stock

Aviv REIT announced the public offering of 8 million shares of common stock at a public offering price of $24.10 per share.

NCAL unveils 2014 Assisted Living Week logo

NCAL unveils 2014 Assisted Living Week logo

The National Center for Assisted Living is encouraging communities to use the 2014 "The Magic of Music" logo to celebrate National Assisted Living Week.

New healthcare educational catalog available

New healthcare educational catalog available

Nasco has released its 2014-2015 Health Care Educational Materials catalog, which focuses on training with versatile medical procedure simulators.